Abstract
Objective:
To investigate the effect of CoenzymeQ10 (CoQ10) on pain severity and cartilage degeneration in an experimental model of rat osteoarthritis (OA).
Materials and methods:
OA was induced in rats by intra-articular injection of monosodium iodoacetate (MIA) to the knee. Oral administration of CoQ10 was initiated on day 4 after MIA injection. Pain severity was assessed by measuring secondary tactile allodynia using the von Frey assessment test. The degree of cartilage degradation was determined by measuring cartilage thickness and the amount of proteoglycan. The mankin scoring system was also used. Expressions of matrix metalloproteinase-13 (MMP-13), interleukin-1β (IL-1β), IL-6, IL-15, inducible nitric oxide synthase (iNOS), nitrotyrosine and receptor for advanced glycation end products (RAGE) were analyzed using immunohistochemistry.
Results:
Treatment with CoQ10 demonstrated an antinociceptive effect in the OA animal model. The reduction in secondary tactile allodynia was shown by an increased pain withdrawal latency and pain withdrawal threshold. CoQ10 also attenuated cartilage degeneration in the osteoarthritic joints. MMP-13, IL-1β, IL-6, IL-15, iNOS, nitrotyrosine and RAGE expressions were upregulated in OA joints and significantly reduced with CoQ10 treatment.
Conclusion:
CoQ10 exerts a therapeutic effect on OA via pain suppression and cartilage degeneration by inhibiting inflammatory mediators, which play a vital role in OA pathogenesis.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Analgesics / pharmacology
-
Analgesics / therapeutic use
-
Animals
-
Cartilage / drug effects*
-
Cartilage / pathology
-
Cytokines / metabolism*
-
Disease Models, Animal
-
Gene Expression Regulation / drug effects
-
Inflammation / metabolism
-
Iodoacetic Acid / pharmacology
-
Male
-
Matrix Metalloproteinase 13 / metabolism
-
Nitric Oxide / metabolism*
-
Nitric Oxide Synthase Type II / metabolism
-
Osteoarthritis / chemically induced
-
Osteoarthritis / drug therapy*
-
Osteoarthritis / metabolism*
-
Osteoarthritis / pathology
-
Pain / complications
-
Pain / drug therapy*
-
Rats
-
Rats, Wistar
-
Receptor for Advanced Glycation End Products
-
Receptors, Immunologic / metabolism
-
Ubiquinone / analogs & derivatives*
-
Ubiquinone / pharmacology
-
Ubiquinone / therapeutic use
Substances
-
Analgesics
-
Cytokines
-
Receptor for Advanced Glycation End Products
-
Receptors, Immunologic
-
Ubiquinone
-
Nitric Oxide
-
Nitric Oxide Synthase Type II
-
Matrix Metalloproteinase 13
-
coenzyme Q10
-
Iodoacetic Acid
Grants and funding
This research was supported by a grant from the Korea Health Technology R&D Project, Ministry for Health, Welfare & Family Affairs, Republic of Korea (grant number A092258), Bio & Medical Technology Development Program of the National Research Foundation (NRF) funded by the Korean government (MEST) (grant number 2012049783). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.